Better Buy: Netflix vs. Gilead Sciences

In today's ­first round matchup of The Motley Fool Better-Buy Tournament, Netflix squares off against Gilead Sciences in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.

Motley Fool Consumer Goods Editor Mark Reeth thinks Netflix (NASDAQ: NFLX  ) is poised for greater growth than ever before. The past year was a good one for the video streamer and DVD deliverer, with total subscriber count increasing by 4 million and its contribution margin improving by about 400 basis points; all of this helped the company become the S&P 500 and Nasdaq 100 best performing stock of 2013. As if that wasn't enough, Netflix has a strong pipeline of original content that will draw additional viewers, which will in turn continue to improve the company's top line. 

Motley Fool analyst Max Macaluso makes the case for Gilead Sciences (NASDAQ: GILD  ) to move on to the next round. Gilead is one of today's biggest biotech companies, with a number of blockbuster drugs already on the market. It also recently launched a potential blockbuster hepatitis C treatment, Sovaldi, and its impressive pipeline also bodes well for the company's future.

Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better-Buy Bracket

This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cast your vote in the poll below the video!


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 18, 2014, at 11:26 PM, Fo45 wrote:

    Netflix is like a pharmaceutical who has an expensive blockbuster drug with 1 year of patent which is delivered to the pharmacies by the competition. So, you can not compare the two Gilead own many blockbuster drugs and has a future while Netflix is a house of card.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2880533, ~/Articles/ArticleHandler.aspx, 9/30/2014 8:08:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement